Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager obrixtamig (BI 764532) in Patients with DLL3-Positive Tumors: Patients with LCNEC
Year: 2025
Type: conference-paper
Source: Pneumologie
Authors: M Wermke, F Saalfeld, V Gambardella, Y Kuboki, A Olatunji, D Morgensztern, C Sayehli, M Miguel F. Sanmamed, E Arriola, J Wolf, L Liza Villaruz, M Studeny, M Bouzaggou, X Fang, E Felip
Institutions: University Hospital Carl Gustav Carus, Technische Universität Dresden, Universitat de València, Hospital Clínico Universitario de Valencia, National Cancer Center Hospital East, Winship Cancer Institute, Clinica Universidad de Navarra, Hospital Del Mar, Hospital del Mar Research Institute, Centro de Investigación Biomédica en Red de Cáncer, University Hospital Cologne, UPMC Hillman Cancer Center, Boehringer Ingelheim (Germany), Boehringer Ingelheim (France), Boehringer Ingelheim (China), Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4408555477